The invention relates to immunogenic peptides comprising T-cell epitopes and oxidoreductase motifs comprising a modified cysteine, and their use in regulating the immune response in subjects.

The present invention relates to stem cells derived from villi adjacent to the chorionic plate (VCP), and a cell therapeutic agent comprising same. Stem cells derived from the tissue of VCP comprising, of the total villi, the region that is ⅓ of the distance from the area adjacent to the chorionic plate up to the villus distal part, and the basal region of the villi, according to the present invention, exhibit uniform growth characteristics, and proliferation characteristics superior to those of stem cells derived from other placental tissue, and exhibit remarkably excellent differentiation into cartilage, bone and fat, thereby being effectively usable in various tissue regeneration treatments requiring the regeneration of cartilage, bone and fat, and, particularly, in cartilage regeneration and osteoarthritis treatment.

The present invention relates to the field of cell culture and recombinant protein or recombinant virus production in mammalian cells. It specifically relates to a novel feed medium providing lactate and high concentrations of cysteine and to a method for culturing mammalian cells or for producing a product of interest, such as a heterologous protein or a recombinant virus, using said feed medium.

An application of MAL33 gene deletion in improving the tolerance of Saccharomyces cerevisiae to inhibitors in a lignocellulose hydrolyzate is provided. The tolerance of the present MAL33 gene-deleted Saccharomyces cerevisiae strain to acetic acid is greatly improved, and the tolerance of the Saccharomyces cerevisiae strain to other typical inhibitors and H.sub.2O.sub.2 in the lignocellulose hydrolyzate is also improved. The lag period of the Saccharomyces cerevisiae strain in a glucose and xylose medium (YPDX) with 3.5 g/L acetic acid is shortened by 24 h. The fermentation period of the Saccharomyces cerevisiae strain to produce ethanol through co-utilization of glucose and xylose is shortened by 20 h. The growth of the Saccharomyces cerevisiae strain in a glucose and xylose medium (YPDX) with a mixed inhibitor and the ethanol production of the Saccharomyces cerevisiae strain through the co-fermentation of glucose and xylose are superior to those of a control strain.

The present invention relates to a method for producing a composition which comprises animal protein, comprising (a) isolating precursor cells from perinatal tissue of a mammal; (b) incubating the precursor cells under conditions which lead to a myogenic differentiation of the precursor cells; and (c) harvesting the cells. The present invention also relates to a method for producing precursor cells from perinatal tissue, to animal protein produced according to the invention, and precursor cells produced according to the invention. The present invention further relates to the use of a culture medium which has a reduced content of methionine in comparison to standard medium, to the differentiation of precursor cells, and to a method for the in vitro production of a meat-like composition.

Some embodiments are directed to a method for preparing a skin substitute, a dermal substitute, to a skin substitute, to a dermal substitute and to a kit for implementing the method. Some other embodiments are directed to a graft that can consist of of a skin substitute and to the use thereof as treating a skin disorder and/or a loss of skin substance.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.

The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.

Provided are an improved culture process for reducing unwanted culture byproducts when a target protein is produced in a glutamine-free cell culture medium, an improved culture process for producing a target protein in a glutamine-free cell culture medium, or an improved culture process for producing a target protein in a glutamine-free cell culture medium.